Lantheus Holdings, Inc. (LNTH) is a leading global provider of diagnostic imaging solutions for the healthcare industry. It was established in 1956, and its core mission has been to pioneer medical imaging. This has been achieved by the company's continued innovation and development of advanced imaging agents and products that assist physicians and other healthcare providers in better understanding of human body, thus facilitating accurate diagnosis, treatment, and monitoring of diseases.
The company's headquartered in North Billerica, Massachusetts, and operates in more than 70 countries worldwide. The diverse product portfolio of Lantheus Holdings, Inc. ground-breaks in areas such as nuclear and ultrasound contrast imaging, radiopharmaceutical products, medical isotopes, and AI-based software solutions. Their flagship product, DEFINITY, is currently the leading ultrasound contrast agent in the U.S. and has significantly contributed to the company's growth and success.
Lantheus Holdings, Inc. is especially renowned for its deep-seated commitment to advancing patient care. This is not just limited to the provision of high-quality imaging diagnostics, but also extends to the company's active involvement in clinical trials and research to shape the future of medical imaging. Their collaborations with top-notch universities and research institutions globally they embrace opportunities for pioneering breakthroughs in the imaging industry.
Moreover, Lantheus Holdings, Inc., through its subsidiary Lantheus Medical Imaging, plays an active role in the manufacture, commercialization, and distribution of diagnostic and therapeutic products. It has positioned itself as a leader in the field of Personalized Medicine by developing precision diagnostics which use data from in-vivo diagnostic procedures and patient history to provide targeted therapeutic treatments.
The company is listed on the NASDAQ Stock Market under the symbol 'LNTH'. From an investment perspective, Lantheus Holdings has displayed robust financial performance, backed by continual growth in its product lines, strategic acquisitions, and persistent efforts in R&D which keeps it at the forefront of the medical imaging industry, thus presenting attractive possibilities for shareholders.
An important aspect of Lantheus Holdings' corporate philosophy is their commitment to sustainability, with a particular focus on minimizing environmental footprint. The company is continuously striving to reduce waste, use energy more efficiently, and limit greenhouse gas emissions, which is a testament to their dedication towards a better future for everyone.
Overall, Lantheus Holdings, Inc. embodies a unique mix of longevity, innovation, commitment to patient care, and sustainability, making it an eminent player in global healthcare solutions. They're dedicated to enhancing the quality and speed of diagnosing illnesses, which will inevitably lead to quicker, more personalized treatments, ultimately improving the health and well-being of patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article provides an AI-generated analysis of Lantheus Holdings Inc. (NASDAQ: LNTH), indicating a neutral near- and mid-term outlook with a positive long-term bias, but elevated downside risk. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths and support/resistance levels for various time horizons.
Lantheus Holdings (LNTH) is considered modestly undervalued, trading near $99.99 with a narrative fair value of approximately $107.74. The company's pipeline, including new radiodiagnostics and radiotherapeutics like BRAVNETSA, OCTEVY, LNTH-2513 GP1, and LNTH-2401, is expected to drive future revenue and margin growth. However, potential risks such as PSMA PET pricing pressure or regulatory setbacks could impact its performance.
Lantheus Holdings (LNTH) is considered modestly undervalued, with a fair value estimated at $107.74 against its current price of $99.99, despite recent short-term share price softening. The company's pipeline of new radiodiagnostics and radiotherapeutics, including BRAVNETSA and late-stage assets, suggests potential for future revenue and margin growth. However, risks such as PSMA PET pricing pressure or regulatory delays could impact its trajectory.
JPMorgan Chase is reportedly leading a $4.25 billion financing deal for Lantheus, with Jefferies joining as a participant. The article from MT Newswires provides an update on this market chatter, though full details are behind a premium paywall.
Lenders are competing for roles in a $4.25 billion financing package to support Curium's acquisition of Lantheus Holdings Inc., with JPMorgan leading the effort. The debt includes a large term loan, a revolving credit line, and a pre-arranged $1.125 billion payment-in-kind facility. This financing is expected to be syndicated to investors next year and will be a key indicator of market appetite for new leveraged loans.
Mizuho downgraded Lantheus Holdings (LNTH) to a Neutral rating, lowering its price target from $115.00 to $109.00, reflecting cautious sentiment from analysts. While LNTH has a strong GF Score™ of 82/100, indicating solid fundamentals, it is currently assessed as 11.9% overvalued by GuruFocus, with a market price of $100.11 against a GF Value™ of $89.47. Investors are advised to approach the stock with caution due to its overvaluation and lack of strong momentum.
This article provides a technical analysis of Lantheus Holdings Inc. (NASDAQ: LNTH) by the Quantitative Research Desk. It indicates a neutral near and mid-term outlook but a positive long-term bias, noting elevated downside risk due to a lack of additional long-term support signals. The analysis includes AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis with support and resistance levels.
Argus has raised its target price for Lantheus Holdings Inc. (LNTH) to $105.00, with the company's current stock price at $100.33. Lantheus Holdings develops diagnostic products for the U.S. healthcare sector. The report, dated October 7, 2026, also mentions other related reports with target price adjustments for various companies.